rc 3095 has been researched along with Angiogenesis, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bajo, AM; Groot, K; Schally, AV; Szepeshazi, K | 1 |
| Baregamian, N; Chung, DH; Evers, BM; Ishola, TA; Kang, J; Mourot, JM; Rychahou, PG | 1 |
2 other study(ies) available for rc 3095 and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers.
Topics: Animals; Antineoplastic Agents; Bombesin; Breast Neoplasms; Female; Fibroblast Growth Factors; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Peptide Fragments; RNA, Messenger; Somatomedins; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2004 |
Bombesin induces angiogenesis and neuroblastoma growth.
Topics: Animals; Anticarcinogenic Agents; Bombesin; Cell Line, Tumor; Cell Proliferation; Gastrin-Releasing Peptide; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Neuroblastoma; Peptide Fragments; Receptors, Bombesin; RNA, Small Interfering; Vascular Endothelial Growth Factor A | 2007 |